SOUTH SAN FRANCISCO, Calif., May 12 /PRNewswire-FirstCall/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), announces that it presented a poster in collaboration with QualityMetric, Inc. describing the development of a patient reported outcomes questionnaire focused on the Health-Related Quality of Life (HR-QoL) aspects of chronic diarrhea in persons living with HIV/AIDS at the 13th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Toronto, Ontario, May 3 through 7, 2008.
Using classic and modern psychometric methods, a single scale comprised of 9 survey questions covering two HR-QoL content areas was developed. The survey questions showed consistency across gender, race and education level, demonstrated a statistically significant greater negative impact on HR-QoL with more frequent and more severe diarrhea symptoms.
Cathy Olufs, President, AIDS Activist Treatment Coalition (ATAC)
stated, "We are fortunate to currently have a wide choice of HIV
medications and combinations. This makes understanding medication side
effects and their impact on a patient's quality of life more important than
ever. Controlling side effects such as diarrhea can help give patients
access to the full armamentarium of anti-retroviral drugs. We are pleased
to see Napo taking the initiative to develop this new instrument to measure
health-related quality of life as affected by diarrhea."
For more information please contract:
Napo Pharmaceuticals, Inc.
Lisa Conte, Chief Executive Officer
1 + 650 616 1902
David Golman, Pharm.D., Senior Director, Clinical Operations
1+ 760 918 5718
About Napo Pharmaceuticals, Inc.
Napo Pharmaceuticals, Inc. focuses on the development and
commercialization of proprietary pharmaceuticals for the global marketplace
in collaboration with local partners. Napo was founded in November 2001,
and is based in California, USA with a subsidiary in M
|SOURCE Napo Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved